15 completed, 6 active not recruiting, 4 unknown, 2 terminated. 13 Phase 2, 8 Phase 3, 6 Phase 1, 3 Not applicable, 1 Early Phase 1.
Follow Inflammatory Breast Cancer: new trials by email Literature Review of Inflammatory Breast Cancer trials Research Report on Inflammatory Breast Cancer
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Conserving Surgery in Inflammatory Breast Cancer After Neoadjuvant Chemotherapy Breast conserving surgery, Radical modified mastectomy - Inflammatory Breast Cancer | Not applicable | Not yet recruiting | Fondazione Policlinico Universitario Agostino Gemelli IRCCS | 300 | 2024-03-01 | 2024-01-23 |
| Onvansertib + Paclitaxel In TNBC Onvansertib, Paclitaxel - Breast Cancer, Invasive Breast Cancer | Phase 1 / Phase 2 | Active not recruiting | Antonio Giordano, MD | 50 | 2022-09-30 | 2026-02-11 |
| A Study to Evaluate Patient Preference for Home Administration of Fixed-Dose Combination of Pertuzumab and Trastuzumab for Subcutaneous Administration in Participants With Early or Locally Advanced/Inflammatory HER2-Positive Breast Cancer Fixed Dose Combination of Pertuzumab and Trastuzumab for Subcutaneous Use (PH FDC SC), Pertuzumab IV, Trastuzumab IV - Early Breast Cancer, Locally Advanced Breast Cancer | Phase 3 | Completed | Hoffmann-La Roche | 346 | 2022-07-05 | 2026-02-10 |
| Refining Local-Regional Therapy for IBC Lymphoscintigraphy - Breast Cancer, Inflammatory Breast Cancer | Not applicable | Recruiting | Dana-Farber Cancer Institute | 50 | 2021-06-02 | 2025-12-29 |
| CAR-macrophages for the Treatment of HER2 Overexpressing Solid Tumors CT-0508, Pembrolizumab - HER2-positive, Adenocarcinoma | Phase 1 | Unknown | Carisma Therapeutics Inc | 48 | 2021-02-02 | 2024-12-18 |
| Screening Magnetic Resonance Imaging of the Brain in Patients With Breast Cancer MRI - Breast Cancer, HER2-positive Breast Cancer | Not applicable | Active not recruiting | Brigham and Women's Hospital | 214 | 2019-07-26 | 2026-09-09 |
| Study of Immunotherapy in Combination With Chemotherapy in HER2-negative Inflammatory Breast Cancer Pembrolizumab Injection, neoadjuvant EC-paclitaxel chemotherapy - Inflammatory Breast Cancer | Phase 2 | Active not recruiting | Institut Paoli-Calmettes | 52 | 2018-08-29 | 2025-09-12 |
| Denosumab as an add-on Neoadjuvant Treatment (GeparX) Denosumab, nab-Paclitaxel, Epirubicin - Breast Cancer Female NOS, Tubular Breast Cancer Stage II | Phase 2 | Completed | GBG Forschungs GmbH | 780 | 2017-02-13 | 2021-02-02 |
| A Phase 2 Study of Eribulin Followed by AC as Preoperative Therapy for HER2-negative Inflammatory Breast Cancer Eribulin, Adriamycin, Cyclophosphamide - Inflammatory Breast Cancer, Human Epidermal Growth Factor 2 Negative Carcinoma of Breast | Phase 2 | Active not recruiting | Dana-Farber Cancer Institute | 22 | 2016-02-26 | 2026-07-06 |
| A Phase III Trial Comparing Two Dose-dense, Dose-intensified Approaches (ETC and PM(Cb)) for Neoadjuvant Treatment of Patients With High-risk Early Breast Cancer (GeparOcto) non-pegylated liposomal doxorubicin, Carboplatin, Paclitaxel - Tubular Breast Cancer Stage II, Tubular Breast Cancer Stage III | Phase 3 | Completed | GBG Forschungs GmbH | 961 | 2014-12-01 | 2017-07-13 |
| Romidepsin and Abraxane in Treating Patients With Metastatic Inflammatory Breast Cancer Romidepsin, Abraxane - HER2-negative Breast Cancer, Inflammatory Breast Cancer | Phase 1 / Phase 2 | Terminated | Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University | 9 | 2014-04-01 | 2025-05-16 |
| Trial of Adjuvant Chemotherapy in Breast Cancer Patients With Pathological Partial Response and Complete Response to Neoadjuvant Chemotherapy Paclitaxel, Cisplatin, Epirubicin - Invasive Ductal Breast Cancer, Tubular Breast Cancer | Phase 3 | Unknown | RenJi Hospital | 290 | 2014-01-01 | 2020-03-23 |
| Weekly Paclitaxel and Cisplatin to Treat Hormone Receptor Positive and Triple Negative Breast Cancer Patients Paclitaxel, Cisplatin, Gonadotropin-releasing hormone agonist - Tubular Breast Cancer, Mucinous Breast Cancer | Phase 2 / Phase 3 | Active not recruiting | RenJi Hospital | 250 | 2013-09-01 | 2023-08-29 |
| Addition of Cisplatin to Neoadjuvant Therapy for T Locally Advanced Breast Cancer Paclitaxel, Cisplatin - Tubular Breast Cancer, Mucinous Breast Cancer | Phase 2 | Completed | RenJi Hospital | 132 | 2013-01-01 | 2017-01-25 |
| Nanoparticle-based Paclitaxel vs Solvent-based Paclitaxel as Part of Neoadjuvant Chemotherapy for Early Breast Cancer (GeparSepto) nab-Paclitaxel, Paclitaxel - Tubular Breast Cancer Stage II, Mucinous Breast Cancer Stage II | Phase 3 | Completed | GBG Forschungs GmbH | 1229 | 2012-07-01 | 2020-08-06 |
| Carboplatin and Paclitaxel Albumin-Stabilized Nanoparticle Formulation Before Surgery in Treating Patients With Locally Advanced or Inflammatory Triple Negative Breast Cancer carboplatin, paclitaxel albumin-stabilized nanoparticle formulation, laboratory biomarker analysis - Inflammatory Breast Cancer, Stage IIA Breast Cancer | Phase 2 | Active not recruiting | City of Hope Medical Center | 67 | 2012-02-15 | 2026-03-30 |
| Addition of Carboplatin to Neoadjuvant Therapy for Triple-negative and HER2-positive Early Breast Cancer Carboplatin, background treatment - Tubular Breast Cancer Stage II, Mucinous Breast Cancer Stage II | Phase 2 / Phase 3 | Completed | GBG Forschungs GmbH | 595 | 2011-08-01 | 2016-02-15 |
| Efficacy and Safety of Bevacizumab in the Neodjuvant Treatment of Inflammatory Breast Cancer Bevacizumab, Cyclophosphamide, epirubicin hydrochloride - Inflammatory Breast Cancer | Phase 1 | Unknown | Association Tunisienne de lutte Contre le Cancer | 30 | 2011-03-01 | 2013-06-19 |
| Accelerated Radiation Therapy After Surgery in Treating Patients With Breast Cancer External beam radiation therapy - Inflammatory Breast Cancer, Invasive Ductal Breast Carcinoma | Phase 2 | Completed | Rutgers, The State University of New Jersey | 69 | 2010-12-21 | 2023-04-20 |
| MUC1 Vaccine for Triple-negative Breast Cancer MUC-1 peptide vaccine, poly ICLC, MUC1 peptide-poly-ICLC adjuvant vaccine - Breast Cancer, Inflammatory Breast Cancer | Early Phase 1 | Completed | Joseph Baar, MD, PhD | 29 | 2009-08-19 | 2018-07-23 |
Showing 20 of 29. Sign in to see all of them.
Inflammatory Breast Neoplasms (29) · Breast Neoplasms (15) · Carcinoma, Ductal, Breast (8) · Breast Neoplasms, Male (4) · Triple Negative Breast Neoplasms (4) · Bile Duct Neoplasms (2) · Carcinoma, Hepatocellular (2) · Carcinoma, Non-Small-Cell Lung (2) · Carcinoma, Ovarian Epithelial (2) · Endometrial Neoplasms (2) · Pancreatic Neoplasms (2) · Prostatic Neoplasms (2) · Stomach Neoplasms (2) · Urinary Bladder Neoplasms (2) · Adenocarcinoma (1)
Breast Diseases (29) · Neoplasms by Site (29) · Skin Diseases (29) · Skin and Connective Tissue Diseases (29) · Neoplasms (28) · Breast Neoplasms (14) · Neoplasms by Histologic Type (11) · Carcinoma (10) · Neoplasms, Ductal, Lobular, and Medullary (10) · Neoplasms, Glandular and Epithelial (10) · Adenocarcinoma (9) · Carcinoma, Ductal (8) · Pathologic Processes (4) · Pathological Conditions, Signs and Symptoms (4) · Adnexal Diseases (2)
Cyclophosphamide (10) · Paclitaxel (10) · Doxorubicin (6) · Epirubicin (6) · Trastuzumab (6) · Albumin-Bound Paclitaxel (4) · Carboplatin (4) · Taxes (4) · 130-nm albumin-bound paclitaxel (3) · Cisplatin (3) · Radiotherapy (3) · pertuzumab (3) · Bevacizumab (2) · Docetaxel (2) · Filgrastim (2)
National Cancer Institute (NCI) (5) · GBG Forschungs GmbH (4) · RenJi Hospital (3) · Dana-Farber Cancer Institute (2) · Antonio Giordano, MD (1) · Association Tunisienne de lutte Contre le Cancer (1) · Brigham and Women's Hospital (1) · Carisma Therapeutics Inc (1) · City of Hope Medical Center (1) · Cylene Pharmaceuticals (1) · Fondazione Policlinico Universitario Agostino Gemelli IRCCS (1) · Fred Hutchinson Cancer Center (1) · Hoffmann-La Roche (1) · Institut Paoli-Calmettes (1) · Joseph Baar, MD, PhD (1)
United States (16) · Germany (4) · China (3) · Tunisia (2) · Argentina (1) · Bosnia and Herzegovina (1) · Brazil (1) · Bulgaria (1) · Canada (1) · Chile (1) · Costa Rica (1) · Croatia (1) · Egypt (1) · France (1) · India (1)
Andreas Schneeweiss, MD, Prof. (1) · Anthony Goncalves, Pr (1) · Antonio C Giordano, MD, PhD (1) · Ayal Aizer, MD, MHS (1) · Bruce Haffty, MD (1) · Faina Nahklis, MD (1) · Filipa Lynce, MD (1) · Gunter von Minckwitz, MD, Prof (1) · Jeanett Wetzel (1) · Jennifer Specht (1) · Jens Uwe Blohmer, MD (1) · Jinsong Lu (1) · Joanne Mortimer, MD, PhD (1) · Joseph Baar, MD (1)
PMID 34252375, PMID 30976202, PMID 33154826, PMID 38129778, PMID 24794243, PMID 25199759, PMID 25534375, PMID 25943350, PMID 26869049, PMID 28315068, PMID 28715532, PMID 30528802, PMID 31488093, PMID 32163106, PMID 33191846, PMID 33330051, PMID 34801353, PMID 35588050, PMID 36441083, PMID 37014668, PMID 38979716, PMID 39726590, PMID 39920391, PMID 40443562, PMID 41024110
2016 (1), 2023 (1), N01CM62204 (1), P30CA072720 (1), U01CA076576 (1), U10CA031946 (1)